Abstract
Lanreotide, a somatostatin analogue, was radioiodinated with 125I to explore the possibility of using 123I labeled lanreotide as a diagnostic radiopharmaceutical for tumors overexpressing somatostatin (SST) receptors. Radioiodination was carried out with 125I using chloramine T as the oxidant. The labeling yield was >90%. Characterization of 125I-Lanreotide was carried out by paper electrophoresis as well as HPLC. 125I-Lanreotide was purified by chromatography using a C18 Sep-Pak column. Radiochemical purity of the purified 125I-Lanreotide thus obtained was >99%. Significant tumor uptake of 125I-Lanreotide was observed in C57BL/6 mice bearing melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
